Catalog No.
DHD17204
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16410
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Tremelimumab, CP-675, CP-675, 206, CP-675206 clone 11.2.1, CAS: 745013-59-6
Clone ID
Ticilimumab
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial, PMID: 31590988
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, PMID: 30242316
Immunotherapy in Small Cell Lung Cancer, PMID: 32899891
Immune checkpoint inhibitors for hepatocellular carcinoma, PMID: 31290997
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial, PMID: 32271377
The role of immunotherapy in small cell lung cancer, PMID: 30637710
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial, PMID: 33285097
Management of immune-related adverse events and kinetics of response with ipilimumab, PMID: 22614989
Antibodies to watch in 2019, PMID: 30516432
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis, PMID: 30409774
Genetic basis for clinical response to CTLA-4 blockade in melanoma, PMID: 25409260
Immune checkpoint inhibitor-induced musculoskeletal manifestations, PMID: 32743706
Durvalumab for the treatment of non-small cell lung cancer, PMID: 31782989
[Classification and etiology of hyperthyroidism], PMID: 24779222
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes, PMID: 29138342
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, PMID: 29576375
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances, PMID: 30380773
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review, PMID: 31374917
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives, PMID: 32392774
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study, PMID: 32294530
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma, PMID: 33046869
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study, PMID: 32379280
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma, PMID: 27816492
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis, PMID: 29778737
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma, PMID: 31954495
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC, PMID: 29991499
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 + Regulatory T Cells (Tregs) in Human Cancers, PMID: 30054281
Immunotherapy for small-cell lung cancer: emerging evidence, PMID: 26882955
Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies, PMID: 31497341
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, PMID: 26337719
IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer, PMID: 32503595
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer, PMID: 32860288
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment, PMID: 32778095
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, PMID: 32971005
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial, PMID: 30383184
Tremelimumab, PMID: 20698721
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors, PMID: 30453170
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder, PMID: 33177001
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer, PMID: 32201234
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer, PMID: 32450531
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients, PMID: 32643323
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol, PMID: 33125909
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma, PMID: 31676670
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade, PMID: 32816849
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study, PMID: 31948903
Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review, PMID: 32000444
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways, PMID: 29855698
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis, PMID: 30716481
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study, PMID: 33355200
Endocrine side effects induced by immune checkpoint inhibitors, PMID: 23471977
For research use only. Not for human or drug use.
